Lanean...
Upregulation of Bcl2 in NSCLC with acquired resistance to EGFR-TKI
Lung cancer has the highest incidence and mortality rate worldwide among all malignancy-associated mortalities, of which non-small cell lung cancer accounts for 80% of all cases. Resistance against epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) develops following 8–12 months...
Gorde:
| Argitaratua izan da: | Oncol Lett |
|---|---|
| Egile Nagusiak: | , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
D.A. Spandidos
2018
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5772989/ https://ncbi.nlm.nih.gov/pubmed/29422965 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2017.7377 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|